In:
Case Reports in Oncology, S. Karger AG, Vol. 10, No. 1 ( 2017-4-18), p. 339-349
Abstract:
We retrospectively analyzed 14 patients with locally advanced squamous cell carcinoma of ethmoid sinus (LASCC-ES) for the feasibility of anterior craniofacial resection (ACFR). Ethmoid cancer treatment comprised alternating chemoradiotherapy (ALCRT; 〈 i 〉 n 〈 /i 〉 = 1), concomitant radiotherapy and intra-arterial cisplatin (RADPLAT; 〈 i 〉 n 〈 /i 〉 = 4) and ACFR ( 〈 i 〉 n 〈 /i 〉 = 9). The 3- and 5-year overall survival (OS) rates of patients were 47.6 and 39.6%, respectively. The 3-year local control (LC) rates of chemoradiotherapy (CRT; ALCRT and RADPLAT) ( 〈 i 〉 n 〈 /i 〉 = 5) and ACFR ( 〈 i 〉 n 〈 /i 〉 = 9) groups were 0 and 66.7% ( 〈 i 〉 p 〈 /i 〉 = 0.012), respectively. The 3-year progression-free survival (PFS) rate of the CRT and ACFR groups were 0 and 55.6% ( 〈 i 〉 p 〈 /i 〉 = 0.018), respectively. The 3-year OS rate of the CRT and ACFR groups were 0 and 76.2% ( 〈 i 〉 p 〈 /i 〉 = 0.005), respectively. Postoperative pathological examinations confirmed positive margins in 3 (33%) of 9 cases. The 3-year LC and PFS rates of cases ( 〈 i 〉 n 〈 /i 〉 = 3) with positive surgical margins were significantly poorer than those of cases ( 〈 i 〉 n 〈 /i 〉 = 6) with negative surgical margins. Although ACFR for LASCC-ES is a feasible treatment, cases with positive surgical margins were more prone to local relapse. Therefore, surgical safety margins should be thoroughly assessed.
Type of Medium:
Online Resource
ISSN:
1662-6575
Language:
English
Publisher:
S. Karger AG
Publication Date:
2017
detail.hit.zdb_id:
2458961-5
Permalink